Metformin gel Iontophoresis: Metformin gel 2% Iontophoresis Combined with Physical Therapy Rehabilitation
Iontophoresis: Iontophoresis with neutral gel Combined with Physical Therapy Rehabilitation
Study summary
This study is designed as a randomized, double-blind, placebo-controlled clinical trial with two parallel groups. All participants will receive a standardized physical therapy rehabilitation program. Participants will be randomly allocated into either a study group receiving metformin iontophoresis or a control group receiving placebo iontophoresis. Both participants and outcome assessors will be blinded to group allocation.
Eligibility
Sex
FEMALE
Min age
50 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria:
* • Postmenopausal women aged 50-70 years.
* Clinical and radiographic diagnosis of knee osteoarthritis according to the American College of Rheumatology criteria.
* Radiographic severity classified as Kellgren-Lawrence grade II or III.
* Chronic knee pain for a duration of at least 3 months.
* Pain intensity ≥4 on the Visual Analog Scale.
* Ability to ambulate independently with or without assistive devices.
* Ability to understand and follow instructions.
* Willingness to participate and provide written informed consent.
Exclusion Criteria:
* • Severe knee osteoarthritis (Kellgren-Lawrence grade IV).
* History of knee surgery or intra-articular injections within the previous 6 months.
* Presence of inflammatory rheumatic diseases such as rheumatoid arthritis or gout.
* Neurological disorders affecting lower limb function.
* Uncontrolled metabolic, cardiovascular, or systemic diseases.
* Current or recent use of metformin or other antidiabetic medications.
* Skin lesions, infections, or hypersensitivity at the iontophoresis site.
* Contraindications to electrotherapy such as pacemakers or implanted electronic devices.
* Body mass index ≥35 kg/m².
* Participation in another clinical trial within the last 3 months.
Primary outcome measure(s)
Pain intensity — at baseline, after 6 weeks and after 12 weeks assessed using the Visual Analog Scale.
Functional status — at baseline, after 6 weeks and after 12 weeks assessed using the WOMAC index
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.